https://www.selleckchem.com/products/ho-3867.html
This trial assessed the utility of applying tumor DNA sequencing to treatment selection for patients with advanced, refractory cancer and somatic mutations in one of four signaling pathways by comparing the efficacy of four study regimens that were either matched to the patient's aberrant pathway (experimental arm) or not matched to that pathway (control arm). Adult patients with an actionable mutation of interest were randomly assigned 21 to receive either (1) a study regimen identified to target the aberrant pathway found in their tum
Like
Comment
Share
